1-11 of 11
Matthew L. Ulrickson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu
Journal: Blood
Blood (2023) 142 (Supplement 1): 894.
https://doi.org/10.1182/blood-2023-174510
Published: 2023
Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, Michael D. Jain, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P McGuirk, Abhinav Deol, Kathleen Dorritie, Alison R Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier L. Munoz, Matthew L. Ulrickson, Jason Westin, Julio C. Chavez, Dilan A Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew A Lunning, Saurabh Dahiya
Journal: Blood
Blood (2023) 142 (Supplement 1): 1032.
https://doi.org/10.1182/blood-2023-179868
Published: 2023
Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Sattva S. Neelapu, Julio C. Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, Andrew Lee, Harry Miao, Olga Nikolajeva, Caron A. Jacobson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4868.
https://doi.org/10.1182/blood-2023-174914
Published: 2023
Journal Articles

Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

Clinical Trials & Observations
Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Journal: Blood
Blood (2022) 140 (21): 2248–2260.
https://doi.org/10.1182/blood.2022015478
Published: 2022
Includes: Supplemental data
Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Sattva S. Neelapu, Julio C. Chavez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub-Agha, Rashmi Khanal, Joseph D. Rosenblatt, Marika Sherman, Jinghui Dong, Alessandro Giovanetti, Yin Yang, Christine Lui, Zahid Bashir, A Scott Jung, Caron Jacobson
Journal: Blood
Blood (2021) 138 (Supplement 1): 93.
https://doi.org/10.1182/blood-2021-148473
Published: 2021
Journal Articles

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chavez
Journal: Blood
Blood (2021) 138 (Supplement 1): 739.
https://doi.org/10.1182/blood-2021-148009
Published: 2021
Journal Articles

Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)

Mahmoud Elsawy, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D. Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Christina To, Marie José Kersten
Journal: Blood
Blood (2021) 138 (Supplement 1): 430.
https://doi.org/10.1182/blood-2021-147598
Published: 2021
Journal Articles

Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, Michael D. Jain, Loretta Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, Andre H. Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Matthew L. Ulrickson, Jason R. Westin, Julio C. Chavez, Miriam T. Jacobs, N Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Saurabh Dahiya, Matthew A. Lunning
Journal: Blood
Blood (2021) 138 (Supplement 1): 3826.
https://doi.org/10.1182/blood-2021-147488
Published: 2021
Journal Articles

A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results

Francisco J. Hernandez-Ilizaliturri, MD, Ian W. Flinn, MD PhD, John Kuruvilla, MD, Sarit E Assouline, MD MSc, Matthew L. Ulrickson, MD, Beth A. Christian, MD, Daniel J. Landsburg, MD, Monic Stuart, MD MPH, Henry Lowman, PhD, Nancy Levin, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-142859
Published: 2020
Journal Articles

Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)

Sattva S. Neelapu, MD, Michael Dickinson, DMed Sci, Matthew L. Ulrickson, MD, Olalekan O. Oluwole, MBBS, MPH, Alex F. Herrera, MD, Catherine Thieblemont, MD PhD, Chaitra S. Ujjani, MD, Yi Lin, MD PhD, Peter A. Riedell, MD, Natasha Kekre, MD MPH, FRCPC, Sven de Vos, MD PhD, Yin Yang, MS, Francesca Milletti, PhD, Lovely Goyal, PhD, Jun Kawashima, MD, Julio C. Chavez, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 49.
https://doi.org/10.1182/blood-2020-134449
Published: 2020
Journal Articles

Sierra Clinical Trial Dosimetry Results Support Low Dose Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] for Targeted Lymphodepletion Prior to Adoptive Cell Therapy

Rajneesh Nath, MD, Eileen M Geoghegan, Matthew L. Ulrickson, MD, Jennifer A Spross, MA, Renee H Lichtenstein, BA, Sandy Konerth, MS, Darrell R. Fisher, PhD, Qing Liang, PhD, Dale Ludwig, PhD BS, Vijay Reddy, MD PhD, Mark S. Berger, MD, Boglarka Gyurkocza, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1958.
https://doi.org/10.1182/blood-2019-128838
Published: 2019